Physician profile
Maya Ramchand
NPI 1366654022
$3,953.83
in general payments reported to CMS, 2019-2025
29 companies · $36.80 in 2025
The $36.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $920 · 2021: $1,069 · 2022: $390 · 2023: $188 · 2024: $122 · 2025: $36.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,031.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $435.05 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $369.43 | 2019-2021 | |
| Novo Nordisk INC | $317.62 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.56 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $180.61 | 2019-2021 | |
| Lilly USA, LLC | $151.85 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $149.15 | 2021-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $136.72 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $133.48 | 2019-2023 | |
| Dexcom, INC. | $131.16 | 2021-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $79.53 | 2020-2022 | |
| Abbvie INC. | $56.19 | 2021-2025 | |
| Sanofi Pasteur INC. | $41.03 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.91 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $29.81 | 2020 | |
| Biogen, INC. | $28.12 | 2021-2022 | |
| Glaxosmithkline, LLC. | $26.43 | 2020-2021 | |
| Amgen INC. | $18.15 | 2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $15.22 | 2023 | Nuedexta |
| Eisai INC. | $15.00 | 2021 | |
| Abbott Laboratories | $13.98 | 2021 | |
| Sk Life Science, INC. | $12.97 | 2023 | |
| Pfizer INC. | $12.77 | 2022 | |
| Seqirus USA INC | $12.10 | 2019 | |
| Ucb, INC. | $11.66 | 2022 | |
| Allergan, INC. | $11.47 | 2019 | |
| Daiichi Sankyo INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Ramchand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.